Shingles Clinical Trial
Official title:
Immunogenicity of the Recombinant Zoster Vaccine (Shingrix ®) in Multiple Sclerosis Patients Treated With Anti-CD20 Antibodies Compared to Controls- a Phase IV Monocentric Study
The purpose of this study is to provide evidence as to whether RZV is immunogenic with an acceptable safety profile in Multiple Sclerosis patients on anti-CD20 treatment.
In this monocentric study, we will assess the immunogenicity and safety of two doses of the adjuvanted recombinant Zoster vaccine (RZV, or Shingrix®) in Multiple sclerosis patients treated with anti-CD20 (ocrelizumab, group 1) compared to healthy controls (group 2). Participants will receive Shingrix® on Day0 and Day60; immunological response will be assessed on Day 0, 1, Day 60, 61, Day90 and Day360. Unsolicited Adverse events of special interest (AESI) will be collected throughout the study period; patients reported outcomes (PROs) will be declared for one week after each vaccination. Safety of MS patients will be monitored through EDSS scoring and MRI before and 1 month after vaccination (D90) and at day 180 and 360 (EDSS scoring only) ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01132716 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
|
N/A | |
| Completed |
NCT01132729 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
|
N/A | |
| Completed |
NCT04099706 -
Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT
|
N/A | |
| Completed |
NCT04540081 -
Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer
|
N/A | |
| Completed |
NCT01527370 -
Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)
|
Phase 3 | |
| Completed |
NCT00534248 -
Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)
|
Phase 3 | |
| Completed |
NCT01262300 -
Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents
|
Phase 1 | |
| Completed |
NCT00576108 -
A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)
|
Phase 2 | |
| Completed |
NCT00109122 -
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
|
Phase 2 | |
| Completed |
NCT04047979 -
Systems Biology of Zoster Vaccine
|
Phase 2 | |
| Active, not recruiting |
NCT05871541 -
A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
|
Phase 1 | |
| Completed |
NCT02114333 -
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
|
Phase 1 | |
| Completed |
NCT00900783 -
A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster
|
Phase 2 | |
| Completed |
NCT01600079 -
ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
|
||
| Active, not recruiting |
NCT02444936 -
ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors
|
Phase 4 | |
| Recruiting |
NCT05554068 -
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
|
Phase 2 | |
| Recruiting |
NCT06238726 -
Nudging Patients to Increase Shingles Vaccination
|
N/A | |
| Completed |
NCT02704572 -
Optimal Timing of Zoster Vaccine After Zoster Illness
|
N/A | |
| Completed |
NCT00300222 -
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
|
Phase 3 | |
| Terminated |
NCT02412917 -
A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia
|
Phase 3 |